Daily Sepsis Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span translational therapeutics and antibiotic stewardship. A mechanistic preclinical study shows roburic acid dual-targets NLRP3 and NCF1 to curb macrophage death and improve outcomes in septic lung injury, while a randomized trial demonstrates 7-day antibiotics are non-inferior to 14 days in uncomplicated neonatal sepsis. A targeted nanotherapy delivering the NLRP3 inhibitor MCC950 to skeletal muscle mitigates sepsis-induced myopathy without evident systemic toxicity.
Research Themes
- Inflammasome and redox-targeted therapy in sepsis
- Antibiotic stewardship in neonatal sepsis
- Nanomedicine for organ-specific complications of sepsis
Selected Articles
1. Dual targeting of NCF1 and NLRP3 by roburic acid orchestrates redox homeostasis and inhibits macrophage death in septic lung injury.
In preclinical CLP sepsis models, roburic acid delivered via nanoparticles reduced lung injury and improved survival. Chemical proteomics and CETSA identified NLRP3 and NCF1 as direct targets, revealing dual inhibition of inflammasome assembly and NOX2-mediated ROS generation to suppress pyroptosis and ferroptosis.
Impact: This study uncovers a dual-target mechanism linking inflammasome inhibition with redox control, offering a comprehensive strategy for septic lung injury. The mechanistic depth and survival benefit in vivo highlight high translational potential.
Clinical Implications: While preclinical, the dual targeting of NLRP3 and NCF1 suggests a therapeutic avenue for sepsis-associated acute lung injury, potentially complementing supportive care and anti-inflammatory strategies.
Key Findings
- RBA nanoparticles significantly attenuated lung injury and improved survival in CLP-induced sepsis.
- Chemical proteomics and CETSA identified NLRP3 (NACHT domain) and NCF1 as direct intracellular targets of RBA.
- Dual inhibition reduced inflammasome assembly and NOX2 complex formation, suppressing pyroptosis and lipid peroxidation-driven ferroptosis.
Methodological Strengths
- Multimodal mechanistic validation (single-cell context, chemical proteomics, CETSA) with in vivo efficacy and survival endpoints
- Nanoparticle delivery system enabling targeted pharmacology
Limitations
- Findings are limited to preclinical animal models; human pharmacokinetics and safety are unknown
- Long-term outcomes and off-target effects were not assessed
Future Directions: Evaluate safety, pharmacokinetics, and biomarkers in large-animal models; explore combination with standard sepsis care and define patient endotypes likely to benefit.
Sepsis-associated acute lung injury (ALI) is characterized by excessive inflammation and macrophage death, yet precise therapeutic targets remain limited. Single-cell sequencing analysis indicates that, with progression of sepsis-induced lung injury, macrophages exhibit diverse cell-death programs with prominent enrichment of pyroptosis-related signatures. Here, we identify Roburic acid (RBA) as a potent inhibitor of septic ALI and elucidate its mechanism using a nanoparticle delivery system (RBA-NPs). We demonstrate that RBA-NPs significantly attenuate lung injury through a bioactive lipid compound library screening and improve survival in cecal ligation and puncture (CLP)-induced sepsis models. Mechanistically, using chemical proteomics and cellular thermal shift assays, we identify NLRP3 and NCF1 as direct intracellular targets of RBA. Primarily, RBA interacts with the NACHT domain of NLRP3 to directly block inflammasome assembly and pyroptosis. Furthermore, RBA binds to NCF1 to inhibit NADPH oxidase 2 assembly; this restores redox homeostasis, which not only reinforces the suppression of pyroptosis but also confers additional protection by inhibiting lipid peroxidation-mediated ferroptosis. Our study reveals a comprehensive therapeutic strategy where RBA targets the NLRP3 inflammasome while coordinating redox homeostasis via NCF1 to resolve septic lung injury.
2. 7-days versus 14-days antibiotic therapy in uncomplicated culture proven neonatal sepsis: a randomized control assessor-blinded trial.
In a single-center, assessor-blinded non-inferiority RCT (n=140 randomized after culture positivity), 7-day antibiotic therapy for uncomplicated neonatal sepsis was non-inferior to 14 days for relapse, with shorter hospital stay and less respiratory support. No deaths or definitive relapses occurred in either arm.
Impact: Provides randomized evidence supporting shorter antibiotic courses in uncomplicated neonatal sepsis, directly informing antibiotic stewardship and resource utilization in NICUs.
Clinical Implications: For culture-proven, uncomplicated neonatal sepsis showing early clinical improvement, a 7-day antibiotic course may be adopted to reduce hospital stay and support needs, pending local validation and careful exclusion of CNS, staphylococcal, and fungal infections.
Key Findings
- Seven-day antibiotic therapy was non-inferior to 14 days for relapse in uncomplicated, culture-proven neonatal sepsis.
- Shorter hospital stay and reduced need for respiratory support were observed in the 7-day arm (p<0.05).
- No deaths or definitive relapses occurred during 35-day follow-up post-therapy.
Methodological Strengths
- Assessor-blinded randomized non-inferiority design with culture-confirmed sepsis
- Systematic follow-up (48 hours post-therapy and weekly for 35 days)
Limitations
- Single-center trial with modest sample size (n=140) limits generalizability
- Exclusion of meningitis, staphylococcal, and fungal infections narrows applicability
Future Directions: Multicenter trials across diverse settings and pathogen spectra, with long-term neurodevelopmental outcomes and antimicrobial resistance endpoints.
UNLABELLED: The trial aimed to establish the non-inferiority of a 7-day antibiotic therapy for uncomplicated neonatal sepsis when compared to the standard 14-day therapy. This study was a parallel-group, randomized non-inferiority assessor-blinded trial conducted in a tertiary Neonatal Intensive Care Unit in Central India. Neonates weighing ≥ 1000 g with suspected sepsis were screened and those meeting criteria were enrolled. Exclusions included babies with CNS (central nervous system) infections, septic arthritis, and life-threatening congenital malformations. Participants were observed for 7 days on antibiotics and re-evaluated; those with positive blood cultures were then randomized to receive either 7 or 14 days of antibiotics. The primary outcome was the relapse of sepsis, and a sample size of 70 in each arm was calculated based on a non-inferiority margin. Follow-ups were conducted for 48 h post-antibiotic treatment and weekly for 35 days to monitor any recurrence of illness. During the study, 917 babies with suspected sepsis were admitted, of which 256 had culture-positive sepsis. After excluding those with meningitis, staphylococcus, and fungal infections, 140 babies showed improvement at day 5 and were randomized into two groups: one receiving antibiotics for 7 days and the other for 14 days, each consisting of 70 babies. Klebsiella pneumoniae was the prevalent organism. The 7-day group had a shorter hospital stay (p < 0.05) and less respiratory support (p < 0.05). Outcomes revealed a low incidence of probable relapse in both groups, with no fatalities or definitive relapses recorded. CONCLUSIONS: A 7-day antibiotic regimen for uncomplicated neonatal sepsis is not inferior to a 14-day regimen. WHAT IS KNOWN: • Unregulated use of antibiotics can lead to a myriad of problems, especially in neonates. • There is some evidence that uncomplicated neonatal sepsis can be treated with short-course antibiotics. WHAT IS NEW: • Data is lacking-especially from Central India. • This trial checks if it is possible to reduce the duration of antibiotic therapy in uncomplicated neonatal sepsis.
3. MCC950-Loaded M12-Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis-Induced Muscle Atrophy.
M12-peptide functionalized liposomes delivered MCC950 selectively to skeletal muscle, enhancing local NLRP3 inhibition. In CLP sepsis, the formulation reduced muscle atrophy, improved grip strength, and lowered Atrogin-1/MuRF1 expression, with no hepatic or renal toxicity observed.
Impact: Demonstrates a targeted, sustained-release strategy that mitigates MCC950 hepatotoxicity while addressing sepsis-induced myopathy, a major driver of long-term disability.
Clinical Implications: If translated, muscle-targeted NLRP3 inhibition could become a disease-modifying approach for sepsis survivors with myopathy, complementing rehabilitation to improve functional recovery.
Key Findings
- M12-liposomes increased skeletal muscle accumulation 3.47–5.31-fold and enhanced intracellular delivery 2.28-fold versus non-targeted controls.
- NLRP3 activation (caspase-1 cleavage and IL-1β/IL-18 secretion) and LPS-induced myotube atrophy were significantly inhibited in vitro.
- In CLP sepsis, treatment reduced muscle atrophy, improved grip strength, and lowered Atrogin-1 and MuRF1 expression without hepatic/renal toxicity.
Methodological Strengths
- Comprehensive nanoformulation characterization with in vitro and in vivo validation
- Safety assessment via histology and serum biochemistry supports translational potential
Limitations
- Preclinical mouse models; human efficacy and dosing remain unknown
- Long-term durability of effect and immunogenicity of the delivery platform not assessed
Future Directions: Study pharmacokinetics, biodistribution, and chronic dosing in large animals; explore combination with rehabilitation and define clinical endpoints for future trials.
BACKGROUND: Sepsis-induced myopathy (SIM) is a severe complication that contributes to late-stage mortality and functional impairment in sepsis patients. The NLRP3 inflammasome plays a pivotal role in the pathogenesis of SIM, and its selective inhibitor MCC950 has shown promising therapeutic potential. However, systemic administration of MCC950 is limited by hepatotoxicity, necessitating the development of targeted delivery systems to enhance efficacy while minimizing toxicity. METHODS: To improve the therapeutic profile of MCC950, we designed M12-functionalized liposomal nanoparticles (M12-Liposome@MCC950 NPs) as the carrier material, with surface modification by the muscle-homing peptide M12 for targeted delivery to skeletal muscle tissue. Nanoparticle characteristics were assessed using transmission electron microscopy (TEM), dynamic light scattering (DLS) and in vitro drug release assays. The targeting efficiency was evaluated in vivo using fluorescence imaging and in vitro via cellular uptake studies in C2C12 myoblasts. The anti-inflammatory and anti-atrophic effects were investigated in an LPS-induced myotube atrophy model and a cecal ligation and puncture (CLP)-induced sepsis mouse model. Biocompatibility and systemic safety were assessed through histological analysis and serum biochemical assays. RESULTS: M12-Liposome@MCC950 NPs exhibited a uniform spherical morphology, an average diameter of 150 ± 10 nm and a zeta potential of -15.73 ± 6.03 mV, ensuring good colloidal stability. The nanoparticles demonstrated sustained drug release over 14 days. In vivo fluorescence imaging confirmed enhanced skeletal muscle accumulation of M12-conjugated nanoparticles, with a 3.47- to 5.31-fold increase compared to nontargeted controls. Cellular uptake studies revealed a 2.28-fold improvement in intracellular delivery efficiency. In vitro, M12-Liposome@MCC950 NPs significantly inhibited NLRP3 inflammasome activation, reducing caspase-1 cleavage and IL-1β/IL-18 secretion, while also preventing LPS-induced myotube atrophy. In the CLP-induced sepsis model, treatment with M12-Liposome@MCC950 NPs markedly reduced muscle atrophy, improved grip strength and decreased expression of atrophy-related proteins Atrogin-1 and MuRF1. Additionally, histological and biochemical assessments confirmed that the nanoparticles did not induce hepatic or renal toxicity, demonstrating excellent biocompatibility. CONCLUSIONS: M12-Liposome@MCC950 NPs provide a targeted and sustained-release strategy for delivering MCC950 to skeletal muscle, effectively inhibiting NLRP3 inflammasome activation and alleviating SIM. This approach enhances therapeutic efficacy while mitigating systemic toxicity, highlighting the potential of nanomedicine-based interventions for treating inflammation-related myopathies.